Delayed emesis: Moderately emetogenic chemotherapy

Supportive Care in Cancer

Volumn 13, Issue 2, 2005, Pages 104-108

  Roila, Fausto ^a   Warr, David ^b   Clark Snow, Rebecca A ^c   Tonato, Maurizio ^a   Gralla, Richard J ^d   Einhorn, Lawrence H ^e   Herrstedt, Jorn ^f  

^a Policlinico Hospital   (Italy)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^d New York Lung Cancer Alliance   (United States)

^e WALTHER CANCER INSTITUTE   (United States)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

5 HT 3 antagonist; Delayed emesis; Dexamethasone; Moderately emetogenic chemotherapy

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; DOLASETRON MESILATE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; GRANISETRON; IRINOTECAN; METOCLOPRAMIDE; METOPIMAZINE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PALONOSETRON; PLACEBO; SEROTONIN 3 ANTAGONIST;

CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; HUMAN; NAUSEA AND VOMITING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; STATISTICAL SIGNIFICANCE; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DEXAMETHASONE; DOPAMINE ANTAGONISTS; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; PRACTICE GUIDELINES; RECEPTORS, SEROTONIN, 5-HT3; VOMITING;

EID: 17644396048     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-004-0700-8     Document Type: Review

References (21)

1. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9:811-819
2. ASHP Commission on Therapeutics (1999) ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm 56:729-764
3. Barrenetxea G, Schneider J, Centeno MM, et al (1996) Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens. Cancer Chemother Pharmacol 38:471-475
4. De Angelis V, Roila F, Sabbatini R, et al (2003) Cancer chemotherapy-induced delayed emesis: antiemetic prescriptions in clinical practice. Proc ASCO 22:739
5. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Cancer 98:2473-2482
6. ESMO Guidelines Task Force (2001). ESMO recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Ann Oncol 12:1059-1060
7. Esseboom EU, Rojer RA, Borm JJ, et al (1995) Prophylaxis of delayed nausea and vomiting after cancer chemotherapy. Neth J Med 47:12-17
8. Gralla RJ, Osoba D, Kris MG, et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971-2994
9. Gralla R, Lichinitser M, Van der Vegt S, et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570-1577
10. Grunberg SM, Hansen M, Deuson R, et al (2002) Incidence and impact of nausea and vomiting with modern antiemetics: perception versus reality. Proc. ASCO 21:250a
11. Herrstedt J, Sigsgaard T, Boesgaard M, et al (1993) Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. New Engl J Med 328:1076-1080
12. Inoue A, Yamada Y, Matsumura Y, et al (2003) Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer 11:528-532
13. Italian Group for Antiemetic Research (1997) Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? Ann Oncol 8:561-567
14. Italian Group for Antiemetic Research (1998) Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Ann Oncol 9:759-765
15. Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554-1559
16. Italian Group for Antiemetic Research (2004) Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 22:725-729
17. Italian Group for Antiemetic Research (2004) Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. Support Care Cancer 12(6):446-453
18. Kaizer L, Warr D, Hoskins P, et al (1994) Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:1050-1057
19. Koo WH, Ang PT (1996) Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 7:71-74
20. Pater JL, Lofters WS, Zee B, et al (1997) The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 8:181-185
21. Stewart A, McQuade B, Cronje JDE, et al (1995) Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide induced emesis in outpatients: a multicentre, double-blind, double dummy, randomised, parallel group study. Oncology 52:202-210